Rodman & Renshaw Downgrades Karyopharm Therapeutics to Neutral

Benzinga · 1d ago
Rodman & Renshaw analyst Michael King downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral.